Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Experimental combo aims to boost immune attack on Hard-to-Treat head and neck cancer

NCT ID NCT07216833

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 22 times

Summary

This early-phase study tests a combination of two drugs—decitabine (a chemotherapy that can 'reawaken' genes) and nivolumab (an immunotherapy that helps the immune system fight cancer)—in people with head and neck cancer that has returned or spread and cannot be cured with local treatments. About 15 participants will receive the drugs to find the safest dose and see if the combination boosts the immune system's ability to attack tumors. The goal is to control the disease, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

    Cleveland, Ohio, 44195, United States

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.